Research progress
A great deal happens behind the scenes at our foundation, and it is not always visible to donors, fundraisers and other supporters. Several times a year, we therefore publish a clear overview of recent highlights, project updates and financial facts. You can read the latest edition on this page. If you would prefer to receive future editions by email, leave your details below.
This page was last updated on 12 November 2025.
Highlights
In July 2024, the renowned Journal of Clinical Oncology published the results of the follow-up study into dendritic cell therapy for pancreatic cancer.
At the end of 2025, the Support Casper Social Impact Fund BV (SCSIF) will be established to invest alongside third parties in projects such as Pepper Therapeutics B.V., which aims to reintroduce phenformin.
In April 2025, The Westlandse Ride and Support Casper unveiled a new flow cytometer at Erasmus MC, funded by the €235,000 raised during the June 2024 event.
In September 2025, 152 participants travelled to southern France for the Tour de Pancreas. They raised more than €278,000, an increase of 46% on 2024.
Update
In 2025, Support Casper worked with Amsterdam UMC, Erasmus MC and Stichting RARE-NL to develop a robust plan for reintroducing phenformin. The plan covers production of the active ingredient in 2025 and phase I and II clinical trials in 2026 and 2027.
A financial controller joined the organisation in August 2025, giving us stronger oversight of our finances.
Support Casper began working with Deltaplan Alvleesklierkanker in November 2025. By pooling resources, knowledge and expertise, we can strengthen collaboration between hospitals across the Netherlands and support more research. We also appointed an additional project coordinator in May 2025.
Financial facts and figures
In 2024, the foundation received €3.3 million from one-off and regular donations, fundraising campaigns and legacies.
Income from January to October 2025 totalled €2.2 million. During the same period, €1 million was invested in new research, with total investment for the year expected to reach €2.2 million. Funded work included stem-cell and DURIPANC research at Erasmus MC and a neuroimmune checkpoint study at LUMC.
The foundation is in a financially sound position. Funds committed to research are held mainly in deposits until they are needed. Apart from the continuity reserve, we do not retain unnecessary cash, so almost all additional donations can be allocated to new research.
Future
Our research portfolio is increasingly focused on clinical studies in virotherapy and immunotherapy that can lead to effective, affordable treatments.
We remain personally involved with our donors and grateful for every contribution. In our tenth-anniversary year, we aim to raise more than in 2024, with a target of €3.5 million.
Support groundbreaking research against pancreatic cancer with a donation